Pharma industry reports 75 deals worth $26.6 billion in July 2021: GlobalData

The industry also reported 112 venture capital (VC) deals worth $3.8 billion in the same month
Read Article

In July 2021, the pharma industry reported 75 deals worth $26.6 billion as compared to the last 12-month average (July 2020 to June 2021) of 105 deals worth $26.6 billion, according to a GlobalData report.

The report also said that the acquisition of Parexel International Corp by EQT Partners AB and Goldman Sachs Asset Management for $8.5 billion; acquisition of Biolegend by PerkinElmer for approximately $5.2 billion; and acquisition of Teneobio by Amgen for $2.5 billion contributed 60.9 per cent of the total deal value during July 2021.

Apart from it, the report said that the industry also reported 112 venture capital (VC) deals worth $3.8 billion in July 2021, compared to the last 12-month average (July 2020 to June 2021) of 170 deals worth $5 billion.

“Prime Medicine, a biotechnology company, raising $200 million in series B round of financing to advance towards clinical indications, expand capabilities of the platform, and further enhance the exceptional promise of Prime Editing; Deep Genomics Inc, an artificial intelligence (AI) therapeutics company, raising $180 million in series C round of financing for ‘Programmable’ RNA therapeutics; and Wugen Inc, a clinical-stage biotechnology company, raising $172 million in series B funding to advance clinical-stage memory NK cell platform, progress Best-In-Class AML programme, and initiate Multiple Solid Tumour Trials, were the major VC deals reported in July 2021,” added the statement.

pharma dealspharma industry growithpharma industry outlookpharma industry revenue growth
Comments (0)
Add Comment